This test is most useful if any of these apply to you.
Atrial fibrillation causes an irregular heartbeat and becomes more common with age. It can allow clots to form in the heart and travel to the brain, causing a stroke. This panel checks two inherited DNA variants in the chromosome region called 4q25: rs2200733 and rs10033464.
Testing both captures associated genetic variation that either result alone can miss. Human studies support their association with atrial fibrillation, especially rs2200733. Their use in directing care is less settled: this pair alone cannot provide a validated personal risk percentage, and testing has not been shown to improve health outcomes.
The test reads DNA, usually extracted from whole blood. It reports which versions you inherited at each position. You normally inherit one copy of each position from each parent, so you can carry zero, one, or two risk copies at either marker.
In the original study, about a third of participants of European descent carried at least one risk variant. About three quarters of the study's Chinese population carried the rs2200733 risk variant. These figures describe the populations studied; they aren't the chance that a carrier will develop atrial fibrillation.
In an early meta-analysis of European studies, each rs2200733 risk copy was associated with about 90% higher odds of atrial fibrillation. The rs10033464 estimate was about a third higher odds per copy. The original Chinese study found a smaller rs2200733 association, about 40% higher odds per copy. These are relative odds, and your starting risk depends on age, blood pressure, other health conditions, and family history.
The markers lie in DNA between genes, near a gene called PITX2. Mouse studies link this gene to heart development. A study of adult human heart tissue found no association between the tested 4q25 risk variants and PITX2 activity in the sampled tissue. Your genotype does not measure gene activity or reveal your heart's structure.
Stroke studies also found an association, strongest for strokes caused by clots from the heart. For rs2200733, the odds were about half again as high per risk copy. That association does not establish a reason to take blood thinners on the basis of this test.
The T version is the risk-associated version at both positions in the usual reporting orientation. The letters describe DNA versions. Read the laboratory's interpretation if your report uses different lettering.
| Your result | What it suggests |
|---|---|
| C/C at rs2200733 and G/G at rs10033464 | Neither tested risk version was detected. Other variants in this region and elsewhere, along with clinical risk factors, can still contribute to atrial fibrillation. |
| C/C at rs2200733, with G/T or T/T at rs10033464 | The smaller association is present despite absence of the rs2200733 risk version. Its estimated effect varies across studies and ancestry groups. |
| C/T or T/T at rs2200733, with G/G at rs10033464 | The stronger association in this pair is present. Two rs2200733 risk copies generally correspond to higher odds than one in studied populations. |
| Risk versions at both positions | Both associated markers are present, supporting inherited susceptibility from this region. Your risk depends on the exact genotypes and cannot be ranked by counting affected markers alone. |
The two positions are linked within the same chromosome region. You cannot turn them into a validated personal risk score by adding their published effects or counting all risk copies equally. Later mapping studies identified additional signals that this panel does not test.
A study of a much broader genetic score found only modest improvement over clinical risk factors, with a larger gain below age 65. That finding does not establish the predictive performance of this two-marker panel.
Use the result alongside your family history, symptoms, blood pressure, and other heart health information. Blood pressure control and weight management matter regardless of genotype. Whether extra rhythm monitoring would help depends on that wider picture; no screening schedule has been validated specifically for these two results.
If you already have atrial fibrillation, observational studies have linked these variants to recurrence after treatment. After catheter ablation, rs2200733 carriers had about 30% higher recurrence rates in a pooled analysis. Ablation blocks abnormal electrical signals in the heart. Another study found roughly twice the recurrence rate after electrical cardioversion in carriers of either marker. Cardioversion uses an electrical shock to restore a regular rhythm. A drug study also linked rs10033464 to treatment response. These findings have not established that choosing treatment using this pair improves outcomes.
A genetic analysis within a randomized trial found no clear difference in the benefit of early rhythm treatment across broad genetic risk scores. That analysis used many variants and did not test treatment decisions based on this panel.
The 2023 American guideline says genetic counseling and testing for rare disease-causing variants may be reasonable when atrial fibrillation starts before age 45 without obvious risk factors. That evaluation looks for inherited heart muscle or electrical disorders that this panel does not cover.
Much of the evidence comes from people of European ancestry. Variant frequency and estimated effects differ between populations, and rs10033464 has not shown an association in every cohort. A risk label also says nothing about whether an irregular rhythm is happening now. A normal genotype result must not delay evaluation of symptoms.
4q25-AF Risk Genotype is best interpreted alongside these tests.